Voluntis and Roche Pharma France have announced that important milestones have been reached in the development of ZEMY, a digital therapeutic developed by Roche Pharma France in partnership with Voluntis since 2015. ZEMY aims to improve care support for breast cancer patients. Its co-construction with various stakeholders (patients, healthcare professionals, etc.) has been critical in developing its medical algorithms and validating its ease of use.
A multi-centre clinical study has been initiated to evaluate adherence to the ZEMY solution as well as potential improvement in patients’ quality of life. Voluntis and Roche will seek regulatory clearance for this innovative software medical device.
In addition, both partners have agreed to broaden their collaboration by extending ZEMY to all solid tumours, through Voluntis’ Theraxium platform. Voluntis and Roche have therefore expanded their licensing and co-development agreement, in which Voluntis acts as the legal manufacturer of ZEMY, heading its technology and regulatory development and Roche leads the clinical evaluation process and the future commercialisation of the solution to oncology centres.
“We have mobilised our complementary expertise to co-develop a solution that could help the self-management of symptoms, while allowing the patient to stay in touch with their care team,” said Pierre Leurent, CEO of Voluntis. “We are very happy to expand our collaboration with Roche, the world leader in oncology, by extending ZEMY to all solid cancers. This partnership rigorously demonstrates how a digital therapeutic can benefit patient care.”
“At Roche, we always want to push ourselves to help patients more,” said Christine Lhomel, Director of Medical Operations and Scientific Relations at Roche Pharma France. “We think that digital therapeutics like ZEMY can help breast cancer patients and one day all cancer patients, better manage the symptoms related to their cancer treatment and thus make their daily lives a little easier.”
